Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
As of 2021, there are 32,100 people with CF recorded on the CF Foundation Registry. Gastrointestinal Dysmotility affects nearly all people with CF and has a significant impact on quality of life. Current management options are limited and there are no other therapies in development. There is therefore a large unmet need for an effective pan-GI prokinetic for people with CF. Renexxion aim to commence clinical trials in the US this year.
"CF has come full circle - CF was initially a gastrointestinal disease, then after treatments for pancreatic exocrine insufficiently improved, it became a respiratory condition, and now, as the pulmonary treatments are improving,
gut disease has once again come into focus."
Review: Ng C., Prayle, A.P. Gastrointestinal Complications of cystic fibrosis.
Paediatrics and Child Health, 2020, 30(10): 345-349.